Ask AI
ProCE Banner Activity

Nursing Considerations for Management of Chronic Lymphocytic Leukemia (CLL) 

PDF

Access this downloadable guide designed specifically for nurses to provide up-to-date chronic lymphocytic leukemia (CLL) management, including guideline-recommended therapies, dosing strategies, and treatment considerations across lines of care. It also highlights key safety profiles, adverse event management, and nursing considerations for commonly used therapies such as BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy

Released: March 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from BeOne Medicines USA Inc. and Lilly.

BeOne Medicines USA Inc.

Lilly

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, oncology nurses, and other healthcare professionals involved in the management of CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain targeted agents to patients with CLL/SLL according to their rationale, mechanisms of action, efficacy, and adverse event profiles 

  • Support patients’ goals and preferences when receiving treatment for newly diagnosed or relapsed/refractory CLL/SLL, considering prognostic variables, comorbidities, duration, and toxicity profiles

  • Evaluate current and emerging efficacy and safety evidence for the use of targeted agents, including CAR T-cells, in first-line, second-line, and later-line treatment of CLL/SLL

  • Identify and manage adverse events associated with targeted agents for CLL/SLL to improve duration on treatment and clinical outcomes

  • Use enhanced communication strategies to support patient engagement in care, including strategies to recognize and address adverse events, drug interactions, and treatment adherence 

Disclosure

Primary Author

Amy Goodrich, RN, MSN, CRNP: consultant/advisor/speaker: AbbVie, BeiGene, Incyte, Lilly.